Identifying key immunological and molecular pathways that drive disease exacerbation in atopic dermatitis - Immunological and molecular pathways in atopic dermatitis

MedImmune Biotech0 个研究点目标入组 90 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•* adults (*18 years of age);and for:
•* group a (n<=30): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score over 15 at time of inclusion, with an uncontrolled AD using a maintenance dose of local topical steroids as mentioned in the outpatient clinic protocol. These patients need oral immunosuppressive drugs to control their AD
•*group b(n<=30): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score over 15 at time of inclusion, with a controlled AD using a maintenance dose of local topical steroids as mentioned in the outpatient clinic protocol
•*group c(n<=15): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score <15 at time of inclusion
•*group d (n<=15): healthy participants without a history of AD, allergic rhinitis or asthma.

•* on systemic therapy at time of recruitment
•* previous receipt of any investigational agent within 4 weeks prior to recruitment or within 5 half-lives of the investigational agent, whichever is longer
•*evidence of other skin conditions, including, but not limited to, T-cell lymphoma or allergic contact dermatitis
•*not willing to be biopsied;group d: a history of AD, allergic rhinitis or asthma.

发起方

MedImmune Biotech